Evidence map›Paper›PMID 30339295›Full record

ArticleJournal of viral hepatitis2019

Polarization of granulocytic myeloid-derived suppressor cells by hepatitis C core protein is mediated via IL-10/STAT3 signalling.

Meng Wang, Yu Ping, Zhiqin Li, Jieyao Li, Zhen Zhang, Dongli Yue, Xinfeng Chen, Liping Wang, Lan Huang, Jianmin Huang and 7 more

Open access · hybridAbstract read
In one paragraph

Article in Journal of viral hepatitis, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.4field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 17 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 3 institutions in 1 country.

Meng WangBiotherapy Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Yu PingBiotherapy Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Zhiqin LiDepartment of Infectious Diseases, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.ORCID 0000-0002-2903-1375
Jieyao LiDepartment of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Zhen ZhangBiotherapy Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Dongli YueDepartment of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Xinfeng ChenBiotherapy Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Liping WangDepartment of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Lan HuangBiotherapy Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Jianmin HuangBiotherapy Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Li YangBiotherapy Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Xuan ZhaoBiotherapy Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Shuangning YangBiotherapy Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Hong LiBiotherapy Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Jijing ShiThe First People's Hospital of Zhengzhou, Zhengzhou, Henan, China.
Jiansheng LiDepartment of Gastroenterology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Yi ZhangBiotherapy Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.ORCID 0000-0001-9861-4681
First Affiliated Hospital of Zhengzhou University · CNZhengzhou People's Hospital · CNZhengzhou University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Myeloid-derived suppressor cells (MDSCs) have been described as suppressors of T-cell function in many malignancies. Impaired T-cell responses have been observed in patients with chronic hepatitis C virus infection (CHC), which is reportedly associated with the establishment of persistent HCV infection. Therefore, we hypothesized that MDSCs also play a role in chronic HCV infection. MDSCs in the peripheral blood of 206 patients with CHC and 20 healthy donors were analyzed by flow cytometry. Peripheral blood mononuclear cells (PBMCs) of healthy donors cultured with hepatitis C virus core protein (HCVc) were stimulated with or without interleukin 10 (IL-10). Compared to healthy donors and certain CHC patients with sustained viral response (SVR), CHC patients without SVR presented with a dramatic elevation of G-MDSCs with the HLA-DR

Indexed as

CD4-Positive T-LymphocytesCD8-Positive T-LymphocytesCell DifferentiationCell PolarityFemaleHepatitis C, ChronicHumansImmunosuppression TherapyInterferon-gammaInterleukin-10Leukocytes, MononuclearLymphocyte ActivationMaleMiddle AgedMyeloid-Derived Suppressor CellsPrognosisIL10 protein, humanInterferon-gammaInterleukin-10nucleocapsid protein, Hepatitis C virusSTAT3 protein, humanSTAT3 Transcription FactorViral Core ProteinsERKHCV-RNA loadIFN-γ productionsustained virological responseT-cells

Identifiers

PMID30339295
PMCPMC7379525
OpenAlexW2896775917

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.